Market Overview

7 Stocks You Should Be Watching Today

Share:
7 Stocks You Should Be Watching Today

Some of the stocks that may grab investor focus today are:

Wall Street expects D.R. Horton, Inc. (NYSE: DHI) to report its quarterly earnings at $0.62 per share on revenue of $3.04 billion. D.R. Horton shares slipped 2.14 percent to close at $28.77 yesterday.

Rackspace Hosting, Inc. (NYSE: RAX) reported better-than-expected results for the third quarter and issued a strong revenue forecast for the current quarter. Rackspace shares climbed 8.93 percent to $29.51 in the after-hours trading session.

Analysts expect Rockwell Automation (NYSE: ROK) to report its quarterly earnings at $1.79 per share on revenue of $1.68 billion. Rockwell Automation shares rose 1.12 percent to $109.00 in after-hours trading.

Lions Gate Entertainment Corp. (USA) (NYSE: LGF) reported weaker-than-expected results for its second quarter on Monday. Lions Gate shares dipped 6.61 percent to $35.75 in the after-hours trading session.

Analysts are expecting Tribune Media Co (NYSE: TRCO) to have earned $0.29 per share on revenue of $493.76 million in the latest quarter. Tribune Media shares gained 0.80 percent to $40.53 in after-hours trading.

Gap Inc (NYSE: GPS) reported a 3 percent drop in its same-store sales for October. However, same-store sales for the third quarter declined 2 percent. The company also issued a weak earnings forecast for the third quarter. Gap shares tumbled 5.76 percent to $26.10 in the after-hours trading session.

Analysts expect Fossil Group Inc (NASDAQ: FOSL) to post its quarterly earnings at $1.13 per share on revenue of $793.72 million. Fossil shares dropped 2.58 percent to close at $53.70 yesterday.

Posted-In: Stocks To WatchEarnings News Guidance Pre-Market Outlook Markets Trading Ideas

 

Related Articles (FOSL + DHI)

View Comments and Join the Discussion!

Taiwan Semiconductor Approved Capital Appropriations of ~$3.96B for Capacity Expansion of Advanced Technology and Packaging and Assembly

Astellas to Acquire Ocata Therapeutics